UnitedHealth Group Inc (NYSE:UNH)‘s stock had its “buy” rating reissued by equities research analysts at Cowen and Company in a research note issued to investors on Friday.

Other equities analysts also recently issued reports about the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $192.00 target price on shares of UnitedHealth Group in a report on Friday, May 19th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $205.00 target price (up from $200.00) on shares of UnitedHealth Group in a report on Saturday, April 22nd. Vetr downgraded shares of UnitedHealth Group from a “buy” rating to a “hold” rating and set a $179.00 target price for the company. in a report on Monday, April 24th. Zacks Investment Research upgraded shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $201.00 target price for the company in a report on Wednesday, June 7th. Finally, Evercore ISI reiterated an “outperform” rating and issued a $185.00 target price on shares of UnitedHealth Group in a report on Wednesday, April 19th. One equities research analyst has rated the stock with a hold rating, twenty-five have given a buy rating and one has given a strong buy rating to the company’s stock. UnitedHealth Group has a consensus rating of “Buy” and a consensus target price of $188.10.

Shares of UnitedHealth Group (UNH) opened at 186.35 on Friday. The stock has a 50 day moving average of $178.98 and a 200-day moving average of $168.66. The stock has a market capitalization of $179.58 billion, a P/E ratio of 23.85 and a beta of 0.63. UnitedHealth Group has a 52-week low of $132.39 and a 52-week high of $188.66.

UnitedHealth Group (NYSE:UNH) last released its quarterly earnings data on Tuesday, April 18th. The healthcare conglomerate reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.17 by $0.20. The firm had revenue of $48.72 billion during the quarter, compared to the consensus estimate of $48.21 billion. UnitedHealth Group had a return on equity of 21.73% and a net margin of 4.50%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.81 earnings per share. Analysts predict that UnitedHealth Group will post $9.80 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Cowen and Company Reiterates Buy Rating for UnitedHealth Group Inc (UNH)” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/07/17/cowen-and-company-reiterates-buy-rating-for-unitedhealth-group-inc-unh.html.

In related news, Director William C. Ballard, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, April 20th. The stock was sold at an average price of $170.47, for a total value of $852,350.00. Following the sale, the director now owns 75,735 shares in the company, valued at $12,910,545.45. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gail R. Wilensky sold 5,540 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The shares were sold at an average price of $178.74, for a total value of $990,219.60. Following the completion of the sale, the director now owns 60,516 shares in the company, valued at approximately $10,816,629.84. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,378 shares of company stock worth $5,285,052. 0.89% of the stock is owned by insiders.

Large investors have recently modified their holdings of the stock. B & T Capital Management DBA Alpha Capital Management increased its position in shares of UnitedHealth Group by 4.9% in the fourth quarter. B & T Capital Management DBA Alpha Capital Management now owns 1,606 shares of the healthcare conglomerate’s stock worth $257,000 after buying an additional 75 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of UnitedHealth Group by 3.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 173,889 shares of the healthcare conglomerate’s stock worth $27,823,000 after buying an additional 5,407 shares during the last quarter. Zurich Insurance Group Ltd FI increased its position in shares of UnitedHealth Group by 10.2% in the fourth quarter. Zurich Insurance Group Ltd FI now owns 132,461 shares of the healthcare conglomerate’s stock worth $21,199,000 after buying an additional 12,235 shares during the last quarter. Guardian Capital LP increased its position in shares of UnitedHealth Group by 18.6% in the fourth quarter. Guardian Capital LP now owns 70,842 shares of the healthcare conglomerate’s stock worth $11,338,000 after buying an additional 11,097 shares during the last quarter. Finally, Scotia Capital Inc. increased its position in shares of UnitedHealth Group by 12.7% in the fourth quarter. Scotia Capital Inc. now owns 48,283 shares of the healthcare conglomerate’s stock worth $7,732,000 after buying an additional 5,451 shares during the last quarter. Hedge funds and other institutional investors own 86.21% of the company’s stock.

About UnitedHealth Group

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.